---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-277937"
form_type: "8-K"
ticker: "NAMS"
cik: "0001936258"
company_name: "NewAmsterdam Pharma Co N.V."
filed_at: "2024-12-13T23:59:59+00:00"
generated_at: "2026-05-29T03:44:35.515040+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# NewAmsterdam Pharma prices $416.5M upsized public offering; net proceeds ~$452.6M

## Summary
- Pricing of 12,117,347 ordinary shares at $24.50/share and 4,882,653 pre-funded warrants at $24.4999/warrant.
- Offering upsized from initial $300M to $416.5M; underwriters exercised option to buy additional 2,550,000 shares.
- Net proceeds to company expected ~$452.6M after underwriting discounts and estimated offering expenses.
- Closing expected on or about December 13, 2024, subject to customary conditions.
- Joint book-running managers: Jefferies, Goldman Sachs, Leerink Partners, TD Cowen, Guggenheim Securities, William Blair.

## SEC filing metadata
- accession: 0001193125-24-277937
- form_type: 8-K
- ticker: NAMS
- cik: 0001936258
- company_name: NewAmsterdam Pharma Co N.V.
- filed_at: 2024-12-13T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1936258/000119312524277937/0001193125-24-277937-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1936258/000119312524277937/d916004d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-277937
- JSON: https://secwatch.observer/filing/0001193125-24-277937.json
- Plain text: https://secwatch.observer/filing/0001193125-24-277937.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.